These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20560817)

  • 21. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.
    Maksymowych WP; Salonen D; Inman RD; Rahman P; Lambert RG;
    J Rheumatol; 2010 Aug; 37(8):1728-34. PubMed ID: 20436073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
    Mugnier B; Roudier J
    Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway.
    Grabar PB; Rojko S; Logar D; Dolzan V
    Ann Rheum Dis; 2010 May; 69(5):931-2. PubMed ID: 20413572
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis.
    Olivieri I; D'Angelo S; Scarano E; Santospirito V; Padula A
    Arthritis Rheum; 2007 Aug; 56(8):2805-7. PubMed ID: 17665436
    [No Abstract]   [Full Text] [Related]  

  • 29. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
    Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When less is more.
    Deodhar A
    J Rheumatol; 2010 Jun; 37(6):1089-90. PubMed ID: 20516035
    [No Abstract]   [Full Text] [Related]  

  • 32. Intraarticular injection of infliximab.
    Sakellariou GT; Kakavouli G; Chatzigiannis I
    J Rheumatol; 2006 Sep; 33(9):1912-3; author reply 1913. PubMed ID: 16960955
    [No Abstract]   [Full Text] [Related]  

  • 33. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B; Balandraud N; Darque A; Roudier C; Roudier J; Reviron D
    Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis.
    Boers M
    Ann Rheum Dis; 2009 Jan; 68(1):1-2. PubMed ID: 19088258
    [No Abstract]   [Full Text] [Related]  

  • 35. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis.
    Pinto JA; Rego I; Rodríguez-Gomez M; Cañete JD; Fernandez-López C; Freire M; Fernandez-Sueiro JL; Sanmarti R; Blanco FJ
    J Rheumatol; 2008 Jan; 35(1):177-8. PubMed ID: 18176993
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis.
    Akbulut H; Koca SS; Ozgen M; Isik A
    J Rheumatol; 2010 May; 37(5):1073-4. PubMed ID: 20439531
    [No Abstract]   [Full Text] [Related]  

  • 40. Pustular skin lesions in patients treated with infliximab: report of two cases.
    Starmans-Kool MJ; Peeters HR; Houben HH
    Rheumatol Int; 2005 Sep; 25(7):550-2. PubMed ID: 15711788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.